Board Of Directors
Management Board
Charles Woler, MD
Chairman of the Board and Chief Executive Officer, ENDOTIS PHARMA SA
Before joining Endotis Pharma, Charles was founder and CEO of Neuro3d, a VC backed biotech company focusing on psychiatric disorders, which was merged with Evotec OIE in May 2007.
Since 1976 he has worked with the Pharma industry in senior positions at Warner Lambert and Akzo Pharma, he became General Manager, France, of Roche, and then Chairman of Smithkline Beecham European pharmaceutical business. Then he moved to the biotech industry in the US to become CEO of Cadus Pharmaceuticals, a NASDAQ listed biotech company.
Chairman of the Board and Chief Executive Officer, ENDOTIS PHARMA SA
Before joining Endotis Pharma, Charles was founder and CEO of Neuro3d, a VC backed biotech company focusing on psychiatric disorders, which was merged with Evotec OIE in May 2007.
Since 1976 he has worked with the Pharma industry in senior positions at Warner Lambert and Akzo Pharma, he became General Manager, France, of Roche, and then Chairman of Smithkline Beecham European pharmaceutical business. Then he moved to the biotech industry in the US to become CEO of Cadus Pharmaceuticals, a NASDAQ listed biotech company.
Rafaele Tordjman, MD, Ph.D.
Partner, Sofinnova Partners
Rafaele Tordjman MD, PhD is a Partner who specialises in life sciences investments. She joined Sofinnova Partners in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Medicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology. Rafaele obtained her medical degree and her specialisation in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the "Young Manager Program" at INSEAD (France in 2002). She has invested in and is on the board of Ascendis, HBI, Preglem, DBV technologies, Endotis and Flexion Therapeutics. She was also on the board of Corevalve and of Endoart before the latter was successfully sold to Allergan Inc.
www.sofinnova.fr
Partner, Sofinnova Partners
Rafaele Tordjman MD, PhD is a Partner who specialises in life sciences investments. She joined Sofinnova Partners in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Medicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology. Rafaele obtained her medical degree and her specialisation in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the "Young Manager Program" at INSEAD (France in 2002). She has invested in and is on the board of Ascendis, HBI, Preglem, DBV technologies, Endotis and Flexion Therapeutics. She was also on the board of Corevalve and of Endoart before the latter was successfully sold to Allergan Inc.
www.sofinnova.fr
Dr C.D. Nicholson, MD
Executive Vice President, R&D, NV Organon
Executive Vice President, R&D, NV Organon
Peter Barton Hutt
Independent
Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling, specializing in Food and Drug Law. As former Chief Counsel for the Food and Drug Administration, he drafted the legislation that was enacted as the Medical Device Amendments of 1976. Mr. Hutt currently serves as a member of the Institute of Medicine of the National Academy of Sciences and has taught since 1994 a course on food and drug law at Harvard Law School. He has published numerous papers on food and drug law and health policy. Mr. Hutt received his bachelor's degree from Yale University, law degree from Harvard University, and a LLM degree from New York University School of Law.
Independent
Peter Barton Hutt is a senior counsel in the Washington, DC law firm of Covington & Burling, specializing in Food and Drug Law. As former Chief Counsel for the Food and Drug Administration, he drafted the legislation that was enacted as the Medical Device Amendments of 1976. Mr. Hutt currently serves as a member of the Institute of Medicine of the National Academy of Sciences and has taught since 1994 a course on food and drug law at Harvard Law School. He has published numerous papers on food and drug law and health policy. Mr. Hutt received his bachelor's degree from Yale University, law degree from Harvard University, and a LLM degree from New York University School of Law.
Pat Zenner
Independent
From 1993 to 2001, Mr. Zenner served as the President and Chief Executive Officer of Hoffmann-La Roche, Inc. Mr. Zenner served in various other capacities with Hoffman-La Roche since 1969, including Senior Vice President of its pharmaceutical division from 1992 to 1993, as Head of International Pharmaceutical Marketing from 1988 to 1992 and as Vice President and General Manager of Roche Laboratories from 1982 to 1988. Mr. Zenner is currently a Director of Curagen, Arqule, Inc., Dendrite International, EXACT Sciences, Inc., First Horizon Pharmaceuticals, Inc., Geron Corporation, West Pharmaceutical Services and Xoma Ltd. Mr. Zenner holds a B.S.B.A. from Creighton University and an M.B.A. from Fairleigh Dickinson University.
Independent
From 1993 to 2001, Mr. Zenner served as the President and Chief Executive Officer of Hoffmann-La Roche, Inc. Mr. Zenner served in various other capacities with Hoffman-La Roche since 1969, including Senior Vice President of its pharmaceutical division from 1992 to 1993, as Head of International Pharmaceutical Marketing from 1988 to 1992 and as Vice President and General Manager of Roche Laboratories from 1982 to 1988. Mr. Zenner is currently a Director of Curagen, Arqule, Inc., Dendrite International, EXACT Sciences, Inc., First Horizon Pharmaceuticals, Inc., Geron Corporation, West Pharmaceutical Services and Xoma Ltd. Mr. Zenner holds a B.S.B.A. from Creighton University and an M.B.A. from Fairleigh Dickinson University.
Stephanie Leouzon
Independent
Stephanie Leouzon is an independent consultant providing advice to life science companies. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised on more than 20 strategic transactions, and been involved in over 45 financing transactions for health care clients.
She also serves as a Senior Advisor to Torreya Partners, a life sciences advisory firm.
Mrs. Leouzon earned an MBA degreee from the Darden Graduate School of Business Administration at the University of Virginia and a BA degreee from Mount Holyoke College.
Independent
Stephanie Leouzon is an independent consultant providing advice to life science companies. Previously she worked in Health Care Investment Banking in the US and Europe from 1989-2010, most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised on more than 20 strategic transactions, and been involved in over 45 financing transactions for health care clients.
She also serves as a Senior Advisor to Torreya Partners, a life sciences advisory firm.
Mrs. Leouzon earned an MBA degreee from the Darden Graduate School of Business Administration at the University of Virginia and a BA degreee from Mount Holyoke College.
Olivier Valdenaire, Ph.D.
Observer to the Board
Dr. Olivier Valdenaire is Venture Partner at Endeavour Vision.
Dr. Valdenaire has been collaborating with the Endeavour Vision team since March 2006. Prior to his entry into the venture capitalist community, he worked as a researcher in the cardiovascular department of Hoffmann-La Roche (Basel); he then co-founded and as CEO helped to develop the Swiss biotech Axovan AG, which was acquired by Actelion in 2003. A trained biologist with a background in mathematics and physics, he graduated from the "Ecole des Mines de Paris" (non-specialised executive engineers) before obtaining a Ph.D. in Neurobiology from Paris (XI) University.
Observer to the Board
Dr. Olivier Valdenaire is Venture Partner at Endeavour Vision.
Dr. Valdenaire has been collaborating with the Endeavour Vision team since March 2006. Prior to his entry into the venture capitalist community, he worked as a researcher in the cardiovascular department of Hoffmann-La Roche (Basel); he then co-founded and as CEO helped to develop the Swiss biotech Axovan AG, which was acquired by Actelion in 2003. A trained biologist with a background in mathematics and physics, he graduated from the "Ecole des Mines de Paris" (non-specialised executive engineers) before obtaining a Ph.D. in Neurobiology from Paris (XI) University.